View printer-friendly version

Download PDF

Emergent BioSolutions and the European Corporate Security Association (ECSA) Sponsor a Conference on Bioterrorism

Attendees Include Key Officials from the European Union, International and Diplomatic Institutions

ROCKVILLE, Md.–(BUSINESS WIRE)–June 5, 2008–Emergent BioSolutions Inc. (NYSE:EBS) co-sponsored the European Corporate Security Association (ECSA) Conference on Bioterrorism. Today’s conference brought together security officials from the European Union, international and diplomatic institutions and delegations, and key figures in the judicial policy and corporate securities communities. It was designed to elevate awareness among professionals in the European Union about the threat of bioterrorism and potential biodefense countermeasures.

Presenters included Dr. Tom Waytes, vice president of medical affairs, Emergent BioSolutions and Jeff MacIntyre of Sabre Technical Services, a New York based company which was responsible for the decontamination process following the anthrax attacks of 2001. Axel Lambert de Rouvroit, a Managing Partner at Health Security Associates in Paris, France, also spoke about emergency logistics and stockpile management from a European Union member state perspective.

In July of last year, the Commission of the European Communities issued a Green Paper on Biopreparedness with the objective to “stimulate a debate and launch a process of consultation at the European level on how to reduce biological risks and enhance preparedness and response.” Emergent BioSolutions responded to the Green Paper, affirming the company’s commitment to reducing bioterrorism and offering its resources to the debate. Today’s conference was an important step in what will be an ongoing dialogue between the company and European and national policy makers.

“We applaud ECSA for initiating this discussion aimed at shining a bright light on the critical issue of global bioterrorism. As the manufacturer of the only FDA approved anthrax vaccine, Emergent has a history of hands on experience which we believe can further enrich this important discussion. We are honored to provide our unique insight which we believe can assist security officials in making a frank assessment of the biopreparedness in Europe,” said Dr. Waytes.

The conference, “Bioterrorism and Preparedness Enhancements” was held at the Domaine Latour de Freins in Brussels, Belgium.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a leading, multinational biopharmaceutical company dedicated to one simple mission — to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Our products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. More information on the company is available at www.emergentbiosolutions.com.